Merck says a trial shows it has produced the first effective antiviral pill for Covid.

[BumRushDaShow]

27. I think in this case

its a cost-benefit type thing. The cost of the infusions / full treatment course for Remdesivir is exorbitant apparently compared to what seems to be suggested for this drug.

Coronavirus drug remdesivir to cost $3,120 per patient with private insurance, irking critics

By Catherine Thorbecke
June 29, 2020, 9:52 AM


The California-based drugmaker Gilead Sciences announced its pricing plans for remdesivir, an antiviral COVID-19 drug candidate, saying the treatment will cost $520 per dose for U.S. private insurance companies and $390 per dose for the U.S. government. For a majority of people who receive a five-day treatment of the drug using six vials (based on current patterns), the total charged to hospitals for patients with private insurance in the U.S. will be $3,120. For those under U.S. government health programs, the total will be $2,340 per patient.

While there are currently no FDA-approved products to treat or prevent COVID-19, remdesivir is the first antiviral medication to show effectiveness against the novel coronavirus in human clinical trials in limiting hospitalization stays. The costs do not represent out-of-pocket costs with a patient using private insurance. That amount would depend on the type of plan they have.

The watchdog group Public Citizen is calling Gilead’s pricing of the drug an "offensive display of hubris and disregard for the public" because of what it estimates to be $70 million in estimated taxpayer money used to develop the drug through federal grants and clinical trials. "Allowing Gilead to set the terms during a pandemic represents a colossal failure of leadership by the Trump administration," said Peter Maybarduk, director of Public Citizen’s Access to Medicines Program.

The pricing for the highly sought-after drugs was explained in an open letter from Daniel O'Day, the chairman and CEO of Gilead Sciences. He wrote, "There is no playbook for how to price a new medicine in a pandemic. O'Day said the company has decided to "price remdesivir well below this value" based on tests that showed remdesivir shortened recovery time by an average of four days.

https://abcnews.go.com/US/covid-19-drug-remdesivir-cost-3120-us-patients/story?id=71509977